INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortress Biotech Inc. - FBIO

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  Fortress Biotech Inc. (“Fortress” or the “Company”) (NASDAQ: FBIO).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Fortress and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On October 1, 2025, Fortress and its subsidiary, Cyprium Therapeutics, Inc., announced receipt of a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration in connection with the New Drug Application for CUTX-101.  Fortress disclosed that the “CRL noted cGMP [Current Good Manufacturing Practice] deficiencies had been observed at the facility where CUTX-101 is manufactured.” 

On this news, Fortress’s stock price fell $1.14 per share, or 30.81%, to close at $2.56 per share on October 1, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Coherent Corp. - COHR

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  Coherent Corp. (“Coherent” or the “Company”) (NYSE: COHR).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Coherent and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On August 13, 2025, Coherent issued a press release “announc[ing] that it has entered into a definitive agreement to sell its Aerospace and Defense business to Advent, a leading global private equity investor, for $400 million.”  Coherent said that “[p]roceeds will be used to reduce debt[.]” 

On this news, Coherent’s stock price fell $22.36 per share, or 19.61%, to close at $91.65 per share on August 14, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Palantir Technologies Inc. - PLTR

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  Palantir Technologies Inc.  (“Palantir” or the “Company”) (NASDAQ: PLTR).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Palantir and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On October 3, 2025, media outlets reported that an internal U.S. Army memo described the NGC2 platform – a battlefield communication system developed by Palantir and Anduril Industries – as a “very high risk” due to security vulnerabilities that could allow adversaries to gain “persistent undetectable access” to the system. 

On this news, Palantir’s stock price fell $13.98 per share, or 7.47%, to close at $173.07 per share on October 3, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Freshpet, Inc. - FRPT

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  Freshpet, Inc. (“Freshpet” or the “Company”) (NASDAQ: FRPT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Freshpet and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On October 8, 2025, Bank of America downgraded Freshpet to Neutral from Buy and cut its price objective to $60 from $81, saying demand for fresh pet food has weakened as consumers rein in spending and pet adoption rates slow. 

Following the downgrade, Freshpet’s stock price fell $3.36 per share, or 6.36%, to close at $49.51 per share on October 8, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stride, Inc. - LRN

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of Stride, Inc. (“Stride” or the “Company”) (NYSE: LRN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Stride and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 14, 2025, Simply Wall St. published a report stating that the Gallup-McKinley County Schools Board of Education had filed a complaint against Stride, alleging fraud, deceptive trade practices, systemic violations of law, and intentional and tortious misconduct, including inflating enrollment numbers by retaining “ghost students” on rolls to secure state funding per student and ignoring compliance requirements, including background checks and licensure laws for its employees. 

Following this news, Stride’s stock price fell $18.60 per share, or 11.75%, to close at $139.76 per share on September 15, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  ACADIA Pharmaceuticals Inc. (“Acadia” or the “Company”) (NASDAQ: ACAD).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Acadia and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 24, 2025, Acadia issued a press release “announc[ing] top-line results from the Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbetocin (ACP-101) in patients with hyperphagia in Prader-Willi syndrome (PWS).”  The press release disclosed that the drug “did not demonstrate a statistically significant improvement over placebo on the study’s primary endpoint, change from baseline to Week 12 on the Hyperphagia Questionnaire for Clinical Trials (HQ-CT), nor was there separation from placebo on any secondary endpoint.”  Acadia’s Head of Research and Development stated that, “given these results, we do not intend to investigate intranasal carbetocin any further.” 

On this news, Acadia’s stock price fell $2.34 per share, or 9.92%, to close at $21.26 per share on September 24, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amer Sports, Inc. - AS

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  Amer Sports, Inc. (“Amer” or the “Company”) (NYSE: AS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Amer and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 19, 2025, Amer’s flagship brand Arc’teryx conducted a promotional fireworks display in Tibet, prompting a backlash from environmentalists and triggering an investigation by Chinese authorities. 

Amer’s stock price subsequently fell $2.18 per share, or 5.82%, to close at $35.27 per share on September 22, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tandem Diabetes Care, Inc. - TNDM

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  Tandem Diabetes Care, Inc. (“Tandem” or the “Company”) (NASDAQ: TNDM).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Tandem and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On August 7, 2025, Tandem disclosed that a malfunction had been identified in certain of the Company’s insulin pumps.  The malfunction could “trigger an error resulting in a discontinuation of insulin delivery,” which “could result in hyperglycemia due to discontinuation of insulin delivery” and “may require hospitalization or intervention from a medical professional.” 

On this news, Tandem’s stock price fell $2.87 per share, or 19.94%, to close at $11.52 per share on August 7, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Freeport-McMoran Inc. - FCX

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  Freeport-McMoran Inc. (“Freeport” or the “Company”) (NYSE: FCX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Freeport and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 9, 2025, Freeport issued a press release announcing the suspension of mining activities at its Grasberg Block Cave operation in Indonesia, after “a large flow of wet material from a production drawpoint . . . blocked access to certain areas within the mine,” trapping seven workers. 

On this news, Freeport’s stock price fell $2.80 per share, or 5.99%, to close at $43.87 per share on September 9, 2025. 

Then, on September 24, 2025, Freeport provided an update on the incident, reporting that two of the seven workers were “fatally injured” and that the remaining five workers “remain missing.” 

On this news, Freeport’s stock price fell $7.69 per share, or 16.95%, to close at $37.67 per share on September 24, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MoonLake Immunotherapeutics - MLTX

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  MoonLake Immunotherapeutics (“Moonlake” or the “Company”) (NASDAQ: MLTX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Moonlake and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 28, 2025, MoonLake reported disappointing results from its Phase 3 VELA trials evaluating the efficacy and safety of sonelokimab.  One trial failed to meet its primary endpoint, while the other showed only modest gains versus placebo. 

Following this news, MoonLake’s stock price fell $55.75 per share, or 89.93%, to close at $6.24 per share on September 29, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Brunello Cucinelli S.p.A. - BCUCY

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  Brunello Cucinelli S.p.A. (“Brunello Cucinelli” or the “Company”) (OTCMKTS: BCUCY).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Brunello Cucinelli and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 25, 2025, Morpheus Research published a report entitled “From Moscow to TJ Maxx - How Brunello Cucinelli Continues To Lie About Its Russian Business While Aggressive Discounting Damages Its Exclusive Positioning.”  The report alleges that, contrary to its own representations, Brunello Cucinelli has continued to unlawfully conduct business in Russia following its invasion of Ukraine. 

On this news, Brunello Cucinelli’s American Depositary Receipt (“ADR”) price fell $2.01 per ADR, or 16.54%, to close at $10.14 per ADR on September 25, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Firefly Aerospace Inc. - FLY

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  Firefly Aerospace Inc. (“Firefly” or the “Company”) (NASDAQ: FLY).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Firefly and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On or around August 7, 2025, Firefly conducted an initial public offering of 19.3 million shares of common stock priced at $45.00 per share.  Then, on September 23, 2025, Firefly reported its financial results for the second quarter of 2025.  Among other items, Firefly reported a loss of $80.3 million, or $5.78 per share, compared to $58.7 million, or $4.60 per share, for the same quarter last year.  Firefly also reported revenue of $15.55 million, below analyst estimates of $17.25 million and down 26.2% from the same quarter last year. 

On this news, Firefly’s stock price fell $7.58 per share, or 15.31%, to close at $41.94 per share on September 23, 2025. 

Then, on September 29, 2025, Firefly disclosed that “[d]uring testing at Firefly's facility in Briggs, Texas, the first stage of Firefly’s Alpha Flight 7 rocket experienced an event that resulted in a loss of the stage.” 

On this news, Firefly’s stock price fell $7.66 per share, or 20.73%, to close at $29.30 per share on September 30, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Informatica Inc. - INFA

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  Informatica Inc. (“Informatica” or the “Company”) (NYSE: INFA).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Informatica and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

We are investigating Informatica Inc. (INFA) (“Informatica” or the “Company”) for potential violations of the federal securities laws.  On February 13, 2025, Informatica reported its fourth quarter of 2024 and fiscal 2024 financial results, missing financial projections.  Specifically, Informatica reported a 3.8% year-over-year decrease in GAAP total revenues, a 2% year-over-year decrease in GAAP subscription revenues, and a 3.9% year-over-year decrease at the midpoint of the range in non-GAAP operating income. 

On this news, Informatica’s stock price fell $5.42, or 21.53%, to close at $19.75 per share on February 14, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of Organogenesis Holdings Inc. (“Organogenesis” or the “Company”) (NASDAQ: ORGO).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   

The investigation concerns whether Organogenesis and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action] 

On September 25, 2025, Organogenesis issued a press release disclosing that a second phase 3 trial of its cryopreserved amniotic suspension allograft ReNu missed its primary endpoint, having failed to achieve a significantly significant change in pain reduction.  The Company said it would ask for a pre-Biologics License Application (BLA) meeting with the U.S. Food and Drug Administration by the end of October to examine a submission pathway, “including using the combined efficacy analysis from both Phase 3 studies to support a BLA approval,” according to Chief Operating Officer Patrick Bilbo.

On this news, Organogenesis’s stock price fell $0.58 per share, or 12.39%, to close at $4.10 per share on September 26, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.    

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rezolve AI PLC - RZLV

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of Rezolve AI PLC (“Rezolve” or the “Company”) (NASDAQ: RZLV).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   

The investigation concerns whether Rezolve and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 29, 2025, Fuzzy Panda Research published a report entitled “Rezolve AI (RXLV): Faking ARR by Acquiring Failing AI Start-ups w/ Declining Revenue; Promotional CEO’s History of False Statements”.  The Fuzzy Panda report alleged, among other things, that although Rezolve “tout[ed] itself as an AI company[,]” it “was really still a mobile phone related tech company” and was “misrepresenting its artificial intelligence capabilities and revenue growth.”

On this news, Rezolve’s stock price fell $0.97 per share, or 16.3%, over the following two trading sessions, to close at $4.98 per share on September 30, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.    

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. (“Larimar” or the “Company”) (NASDAQ: LRMR).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   

The investigation concerns whether Larimar and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 29, 2025, Larimar issued a press release announcing data from an ongoing long-term open-label study evaluating daily subcutaneous injections of Nomlabofusp in participants with Friedreich’s Ataxia.  Although Larimar characterized the data as “positive”, the press release disclosed that anaphylaxis or a severe allergic reaction was reported in seven participants. 

On this news, Larimar’s stock price fell $1.72 per share, or 33.66%, to close at $3.38 per share on September 29, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DexCom, Inc. - DXCM

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether DexCom and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 18, 2025, Hunterbrook Media (“Hunterbrook”) published a short report entitled “Dexcom’s Fatal Flaws”.  The Hunterbrook report alleged, among other things, that Dexcom “made an unauthorized design change to a key component of the G7”, the Company’s continuous glucose monitoring system for diabetes management, and that “G7 users have been hospitalized and died” following inaccurate glucose readings from G7 devices. 

On this news, Dexcom’s stock price fell $8.99 per share, or 11.76%, over the following two trading sessions, to close at $67.45 per share on September 19, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MediaAlpha, Inc. - MAX

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  MediaAlpha, Inc. (“MediaAlpha” or the “Company”) (NYSE: MAX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether MediaAlpha and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On June 24, 2024, Wolfpack Research published a report entitled “MAX: Our Investigation Reveals MAX Is Participating in Consumer Fraud.”  In pertinent part, Wolfpack announced that it was “short the insurance lead generator, MediaAlpha, Inc. (NYSE: MAX) following our research into the company’s [Health Insurance] segment[.]”  Wolfpack stated that it believed “[MediaAlpha] uses dishonest and sometimes outright fraudulent ads along with deceptive websites to trick consumers into providing their personal information in exchange for a health insurance ‘quote.’  [MediaAlpha] then sells this information as raw lead data or uses it to generate clicks or calls for its lead-buying partners.  Our investigation indicates as much as 78% of [MediaAlpha’s] Health [Insurance] lead-buying partners are running boiler room health insurance scams or are flagrantly violating laws concerning telemarketing.” 

On this news, MediaAlpha’s stock price fell $1.92 per share, or 11.84%, over the following two trading sessions, to close at $14.29 per share on June 25, 2024. 

Then, on November 4, 2024, MediaAlpha disclosed receipt of a letter from the Federal Trade Commission (“FTC”) staff stating that the FTC staff was “prepared to recommend the filing of a complaint against the Company,” claiming that MediaAlpha falsely “represented itself as affiliated with government entities, made misleading claims (in particular regarding health insurance products and use of consumers' personal information) and utilized deceptive advertising.” 

On this news, MediaAlpha’s stock price fell $4.46 per share, of 27.7%, to close at $11.62 per share on November 5, 2024. 

Then, on August 6, 2025, MediaAlpha announced it was settling claims with the FTC for $45 million.  According to the FTC’s complaint, MediaAlpha would use advertisements and websites claiming to provide health insurance quotes to collect information from consumers looking for insurance, while in reality, MediaAlpha sold nothing to consumers, and the consumer information it collected would be sold to telemarketers.  According to the FTC, MediaAlpha sold approximately 119 million leads about consumers in 2024 alone.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celanese Corporation - CE

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  Celanese Corporation (“Celanese” or the “Company”) (NYSE: CE).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Celanese and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On November 4, 2024, Celanese issued a press release reporting its financial results for the third quarter of 2024.  Celanese’s reported earnings adjusted for one-time items in the third quarter were $2.44 per share, compared with a consensus estimate of $2.84 per share.  Celanese also reported revenue of $2.65 billion, representing a 2.6% year-over-year decline and falling short of consensus estimates of $2.69 billion.  In the press release, Celanese’s Chief Executive Officer stated that “[i]n the third quarter, we faced a severely constrained demand environment that, in some cases like auto, degraded swiftly” and cautioned investors that “[w]e expect demand conditions to worsen in the fourth quarter, as automotive and industrial segments react to recent dynamics by seasonally destocking at heavier than normal levels.” 

On this news, Celanese’s stock price fell $32.50 per share, or 26.32%, to close at $91.00 per share on November 5, 2024. 

Then, on February 18, 2025, Celanese issued a press release reporting its financial results for the fourth quarter and full year 2024.  Among other items, Celanese “reported full year 2024 U.S. GAAP diluted loss per share of $13.86 and adjusted earnings per share of $8.37”, as well as “net sales of $10.3 billion in 2024, a 6 percent decrease from the previous year consisting of a 4 percent decline in price and a 1 percent decline in volume, with a small currency impact.”  Celanese attributed its results to “[p]ersistently weak global demand in critical end-markets like automotive, paints, coatings, construction and industrial[.]” 

On this news, Celanese’s stock price fell $15.00 per share, or 21.46%, to close at $54.91 per share on February 19, 2025. 

Then, on August 11, 2025, Celanese reported disappointing financial results for yet another quarter.  Among other items, Celanese said that volumes in its Engineered Materials segment were still below normal levels due to easing of destocking in Europe. 

On this news, Celanese’s stock price fell another $6.20 per share, or 13.07%, to close at $41.22 per share on August 12, 2025. 

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of The Hain Celestial Group, Inc. - HAIN

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  The Hain Celestial Group, Inc. (“Hain” or the “Company”) (NASDAQ: HAIN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Hain and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 15, 2025, Hain issued a press release reporting its financial results for the fourth quarter and fiscal year 2025.  Acknowledging Hain’s disappointing results, the Company’s interim Chief Executive Officer said that “[w]e are taking decisive action to optimize cash, deleverage our balance sheet, stabilize sales, and improve profitability as we recognize our performance has not met expectations[.]” 

On this news, Hain’s stock price fell $0.53 per share, or 24.65%, to close at $1.62 per share on September 15, 2025. 

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.